U.S. Markets open in 4 hrs 57 mins

Acceleron Pharma Inc. (XLRN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
128.24+0.92 (+0.72%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close127.32
Open126.37
Bid0.00 x 1000
Ask0.00 x 1100
Day's Range125.23 - 129.00
52 Week Range85.58 - 146.15
Volume579,944
Avg. Volume331,263
Market Cap7.784B
Beta (5Y Monthly)0.41
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Ongoing Treatment With Acceleron's Sotatercept Continue To Show Benefit In PAH Patients
    Benzinga

    Ongoing Treatment With Acceleron's Sotatercept Continue To Show Benefit In PAH Patients

    Acceleron Pharma Inc (NASDAQ: XLRN) has announced interim results from the open-label extension of the PULSAR Phase 2 trial evaluating sotatercept in patients with pulmonary arterial hypertension (PAH). The data were presented at the American Thoracic Society 2021 International Conference. Investigators reported that patients experienced consistent or improved responses in multiple efficacy endpoints when treated with sotatercept for up to 48 weeks. Additionally, patients re-randomized to receive sotatercept on top of background therapies during weeks 24 to 48, after receiving placebo plus stable background therapy during the first 24 weeks of the trial, experienced clinical improvements consistent with those seen in the initial placebo-controlled treatment period. Sotatercept was generally well-tolerated. In the trial, serious treatment-emergent adverse events were reported in 28% of patients, and 9% of patients had adverse events that led to study discontinuation. See the ATS 2021 presentation here. Price Action: XLRN shares are down 0.55% at $123.9 during the market session on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaTreace Medical's Lapiplasty 3D Associated With Early Weightbearing After Foot Surgery, Interim Data ShowsNew Five-Year Data Shows Durable Efficacy Of AstraZeneca's Fasenra For Asthma Treatment© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Here's Why We're Not At All Concerned With Acceleron Pharma's (NASDAQ:XLRN) Cash Burn Situation
    Simply Wall St.

    Here's Why We're Not At All Concerned With Acceleron Pharma's (NASDAQ:XLRN) Cash Burn Situation

    We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

  • 10 Best Pharmaceutical Stocks to Buy According to Billionaire Kerr Neilson
    Insider Monkey

    10 Best Pharmaceutical Stocks to Buy According to Billionaire Kerr Neilson

    In this article we will take a look at the 10 best pharmaceutical stocks to buy according to billionaire Kerr Neilson. You can skip our detailed analysis of the pharmaceutical industry’s outlook for 2021 and some of the major growth catalysts for pharmaceutical stocks and go directly to the 5 Best Pharmaceutical Stocks to Buy […]